TRASTUZUMAB

Description

Pertuzumab/Trastuzumab (Phesgo) – Targeted Therapy for HER2-Positive Breast Cancer

Overview

Pertuzumab/Trastuzumab (Phesgo) is a prescription combination therapy for HER2-positive breast cancer. It contains two monoclonal antibodies—pertuzumab and trastuzumab—designed to block the HER2 receptor, a protein that promotes the growth of certain breast cancer cells. Phesgo is formulated as a fixed-dose subcutaneous injection, offering a faster, convenient alternative to intravenous infusion, while maintaining effective targeted therapy for early-stage and metastatic HER2-positive breast cancer.

Key Features / Indications

• Active Ingredients: Pertuzumab and Trastuzumab
• Therapeutic Class: Monoclonal Antibody / Targeted Therapy
• Indications:

o Early-stage HER2-positive breast cancer (adjuvant therapy)

o HER2-positive metastatic breast cancer

o Often administered with chemotherapy for enhanced effectiveness

• Administration: Subcutaneous injection under medical supervision
• Mechanism of Action: Dual HER2 blockade prevents cancer cell growth, promotes cell death, and reduces tumor progression
• Benefits:

o Combines two effective HER2-targeted therapies in a single injection

o Shorter administration time compared to intravenous therapy

o Improves patient convenience and adherence

o Enhances treatment outcomes in HER2-positive breast cancer

Why Choose Oncomed Pharmacy?

Oncomed Pharmacy provides authentic, high-quality Pertuzumab/Trastuzumab (Phesgo) with professional handling, storage, and guidance for safe administration. Our pharmacists support patients with dosing instructions, side-effect management, and ongoing care to ensure safe and effective therapy. Choosing Oncomed Pharmacy ensures reliable access to this advanced HER2-targeted therapy with dedicated patient support throughout treatment.

Uses of Medicine

Pertuzumab/Trastuzumab (Phesgo) is used for:

• Treating early-stage and metastatic HER2-positive breast cancer
• Blocking HER2 receptors to prevent cancer cell growth
• Supporting combination therapy with chemotherapy for improved outcomes
• Reducing tumor progression and improving patient survival
• Offering convenient subcutaneous administration for patient comfort